Does Rallies show Form 4 insider transactions for ATAI?

Yes. Rallies tracks ATAI insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ATAI research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ATAI. It does not provide personalized investment advice.

ATAI (AtaiBeckley Inc. Common Stock) Stock Analysis - Insider Trades

AtaiBeckley Inc. Common Stock (ATAI) is a publicly traded Healthcare sector company. As of May 21, 2026, ATAI trades at $4.14 with a market cap of $1.53B and a P/E ratio of -4.84. ATAI moved +3.41% today. Year to date, ATAI is +5.68%; over the trailing twelve months it is +99.51%. Its 52-week range spans $1.03 to $6.75. Analyst consensus is strong buy with an average price target of $14.90. Rallies surfaces ATAI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ATAI stock inside the company?

Recent ATAI insider activity includes Craig Kevin James sold 42.58K, Craig Kevin James sold 100.00K, Feilding-Mellen Cosmo sold 39.59K, Apeiron Investment Group Ltd. bought 8.68M, and Apeiron Investment Group Ltd. bought 1.80M. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ATAI Key Metrics

Key financial metrics for ATAI
Metric	Value
Price	$4.14
Market Cap	$1.53B
P/E Ratio	-4.84
EPS	$-0.83
Dividend Yield	0.00%
52-Week High	$6.75
52-Week Low	$1.03
Volume	4.57K
Avg Volume	0
Revenue (TTM)	$3.02M
Net Income	$-154.30M
Gross Margin	0.00%

Recent ATAI Insider Trades

Craig Kevin James sold 42.58K (~$212.90K) on Apr 20, 2026.
Craig Kevin James sold 100.00K (~$355.00K) on Mar 20, 2026.
Feilding-Mellen Cosmo sold 39.59K (~$154.38K) on Jan 2, 2026.
Apeiron Investment Group Ltd. bought 8.68M (~$19.00M) on Aug 14, 2025.
Apeiron Investment Group Ltd. bought 1.80M (~$2.52M) on Mar 24, 2025.

Latest ATAI News

Jefferies Highlights H2 2026 Pivotal Readouts in AtaiBeckley Pipeline — May 13, 2026
AtaiBeckley Sets Q2 2026 Phase 3 Launch for MDMA Depression Therapy — May 12, 2026
AtaiBeckley Gets $209.9M Runway, Begins BPL-003 Phase 3, Eyes Q4 VLS-01 Data — May 12, 2026
AtaiBeckley Wins OVID Health Silver Award and Secures FDA Priority Review Voucher — Apr 27, 2026
Atai Life Sciences Gains as Trump Fast-Tracks Psilocybin and MDMA Therapies — Apr 20, 2026

ATAI Analyst Consensus

11 analysts cover ATAI: 0 strong buy, 11 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $14.90.

Common questions about ATAI

Who is trading ATAI stock inside the company?: Recent ATAI insider activity includes Craig Kevin James sold 42.58K, Craig Kevin James sold 100.00K, Feilding-Mellen Cosmo sold 39.59K, Apeiron Investment Group Ltd. bought 8.68M, and Apeiron Investment Group Ltd. bought 1.80M. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ATAI?: Yes. Rallies tracks ATAI insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ATAI research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ATAI. It does not provide personalized investment advice.